Murat KOÇER, Özgür ÖNAL, Hande Nur EROĞLU, Servet Derya YILMAZ, Dilek KARADOĞAN, İsmet EROĞLU

Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer

Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the time of the diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer. Materials and methods: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Süleyman Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the medical oncology outpatient clinic. Results: A total of 518 patients were evaluated, including 260 patients with squamous cell carcinoma, 207 patients with adenocarcinoma, 50 patients with non-small cell lung cancer-not otherwise specified, and 1 patient with large cell carcinoma. The average life expectancy was found to be 11.50 ± 1.40 months in patients with squamous cell carcinoma, 12.60 ± 1.59 months in patients with adenocarcinoma, and 8.70 ± 1.87 months in the other patients. The estimated 5-year relative survival rate for non-small cell lung cancer was 8% (7% for men and 18% for women). In the multivariate analysis, sex being male (HR, 2.41; P < 0.001), a performance status >2 (HR, 1.70; P < 0.001), the stage of cancer (HR, 1.37; P = 0.045), the presence of bone or liver metastasis (HR, 1.44, P = 0.009, HR, 1.57; P = 0.016, respectively), and the patient not having received radiotherapy (HR, 3.25; P < 0.001) or chemotherapy (HR, 1.85; P = 0.001) were defined as statistically significant predictive factors that reduced the overall survival. Conclusions: In this study, sex, stage, performance status, the presence of liver or bone metastases, and treatment had an effect on overall survival.

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians 2018; 68 (6): 394- 424. doi: 10.3322/caac.21492
2. Gültekin M, Boztaş G. Türkiye kanser istatistikleri. Ministry of Health, Public Health Agency of Turkey; 2014; 43.
3. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128 (1): 452-462. doi: 10.1378/chest.128.1.452
4. Howlader N, Noone AM, Krapcho M, Miller D, Brest A et al. SEER cancer statistics review, 1975-2015. National Cancer Institute; 2015.
5. Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 1999; 23(2): 143-152. doi: 10.1016/s0169- 5002(99)00009-4
6. Gazdar AF, Schiller JH. Predictive and Prognostic Factors for Non–Small Cell Lung Cancer Potholes in the Road to the Promised Land. Journal of the National Cancer Institute 2011; 103 (24): 1810-1811. doi: 10.1093/jnci/djr497
7. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982; 5(6): 649-656. doi: 10.1097/00000421-198212000-00014
8. Rami‐Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Cancer Journal for Clinicians 2017; 67 (2): 138-155. doi: 10.3322/caac.21390
9. Wang T, Nelson RA, Bogardus A, Grannis Jr FW. Five-year lung cancer survival. Cancer 2010; 116 (6): 1518-1525. doi: 10.1002/ cncr.24871
10. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods in Moleculer Biology 2009; 471: 469-486. doi: 10.1007/978-1-59745-416-2_24
11. Radzikowska E, Roszkowski K, Głaz P. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Annals of Oncology. 2002; 13 (7): 1087-1093. doi: 10.1093/ annonc/mdf187
12. Hespanhol V, Queiroga H, Magalhaes A, Santos A, Coelho M et al. Survival predictors in advanced non-small cell lung cancer.Lung Cancer 1995; 13 (3): 253-267. doi: 10.1016/0169- 5002(95)00497-1
13. Campobasso O, Invernizzi B, Musso M, Berrino FJ. Survival rates of lung cancer according to histological type.British Journal of Cancer 1974; 29 (3): 240-246. doi: 10.1038/bjc.1974.63
14. Cunha Santos G, Lai SW, Saieg MA, Geddie WR, Pintilie M et al. Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. Lung Cancer 2012; 77 (3): 501-506. doi: 10.1016/j.lungcan.2012.05.091
15. Cheng T-YD, Cramb SM, Baade PD, Youlden DR, Nwogu C et al. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. Journal of Thorac Oncology 2016; 11 (10): 1653-1671. doi: 10.1016/j.jtho.2016.05.021
16. Cetin K, Ettinger DS, Hei Y, O’Malley CD. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clinal Epidemiology 2011; 3: 139. doi: 10.2147/CLEP.S17191
17. VanderMeer R, Chambers S, Van Dam A, Cutz J, Goffin J et al. Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care? Current Oncology 2015; 22(4): 272-278. doi: 10.3747/co.22.2526
18. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L et al. The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review. Journal of Thoracic Oncology. 2008; 3 (12): 1468-1481. doi: 10.1097/ JTO.0b013e318189f551
19. Nakamura H, Ando K, Shinmyo T, Morita K, Mochizuki A et al. Female gender is an independent prognostic factor in nonsmall-cell lung cancer: a meta-analysis. Annals of Thoracic Cardiovasculer Surgery 2011; 17 (5): 469-480. doi: 10.5761/atcs. oa.10.01637
20. Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR et al. Gender differences in non–small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Annals of Thoracic Cardiovasculer Surgery 2004; 78 (1): 209- 215. doi: 10.1016/j.athoracsur.2003.11.021
21. Paralkar VR, Li T, Langer CJ. Population characteristics and prognostic factors in metastatic non–small-cell lung cancer: a fox chase cancer center retrospective. Clinical Lung Cancer 2008; 9 (2): 116-121. doi: 10.3816/CLC.2008.n.018
22. Buccheri G, Ferrigno D. Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung Cancer 2001; 34 (3): 433-440. doi: 10.1016/s0169- 5002(01)00273-2
23. Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996; 15( 1): 67-77. doi: 10.1016/0169-5002(96)00571-5
24. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S et al. Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLC. Journal of Thoracic Oncology 2010; 5 (5): 620- 630. doi: 10.1097/JTO.0b013e3181d2dcd9
25. Hendriks LE, Derks JL, Postmus PE, Damhuis RA, Houben RMA et al. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV nonsmall cell lung cancer: Results from a population-based study. Europen Journal of Cancer 2015; 51 (17): 2534-2544. doi: 10.1016/j.ejca.2015.08.008
26. Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer.Moleculer and Clinical Onkology 2015; 3(1): 217-221. doi: 10.3892/mco.2014.410
27. Saad F, Lipton A, Cook R, Chen YM, Smith M et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007; 110(8): 1860-1867. doi: 10.1002/cncr.22991
28. Görg C, Schwerk W, Wolf M, Havemann KJBI. Prognostic value of response to chemotherapy using ultrasound in lung cancer with metastatic liver involvement. Bildgebung 1990; 57 (3-4): 70-73. doi: 10.1016/0169-5002(91)91573-T
29. Yamamoto N, Tamura T, Fukuoka M, Saijo N. Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. International Journal of Oncology 1999; 15 (4): 737-778. doi: 10.3892/ijo.15.4.737
30. Finkelstein DM, Ettinger DS, Ruckdeschel JJJoCO. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. Journal of Clinical Onkology 1986; 4 (5): 702-709. doi: 10.1200/JCO.1986.4.5.702
31. Martini N, Rusch VW, Bains MS, Kris MG, Downey RJ et al. Factors influencing ten-year survival in resected stages I to IIIA non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 1999; 117 (1): 32-38. doi: 10.1016/ s0022-5223(99)70467-8
32. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings 2008; 83(5): 584-594. doi: 10.4065/83.5.584
33. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? Jornal of Clinical Oncology 1993; 11 (10): 1866-1872. doi: 10.1200/JCO.1993.11.10.1866
34. Alberti W, Anderson G, Bartolucci A, Bell D, Villalba J et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials.Lung Cancer 1996; 1 (14): 167-168. doi: 10.1136/ bmj.311.7010.899
35. Group NM-AC. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. Journal of Clinical Oncology 2008; 26 (28): 4617-4625. doi: 10.1200/ JCO.2008.17.7162
36. Roswit B, Liberson S, Ohanian M, Kusik H, Petrovich Z. Survival with inoperable lung cancer. Controlled national Veterans Administration study of radiation and chemotherapy. New York State Journal of Medicine. 1976; 76 (4): 560-564. doi: 10.1038/bjc.1977.181
37. Wolf J, Patno ME, Roswit B, D’Esopo N. Controlled study of survival of patients with clinically inoperable lung cancer treated with radiation therapy. The American Journal of Medicine. 1966; 40 (3): 360-367. doi: 10.1016/0002-9343(66)90131-8
38. Pritchard RS, Anthony SP. Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer:A Meta-Analysis. Annals of Internal Medicine 1996; 125 (9): 723-729. doi: 10.7326/0003-4819-125-9-199611010- 00003
39. O’Rourke N, Macbeth F. Is concurrent chemoradiation the standard of care for locally advanced non-small cell lung cancer? A review of guidelines and evidence. Clinical Oncology 2010; 22 (5): 347-355. doi: 10.1016/j.clon.2010.03.007.